ReviewDrug design, development and therapy2026
Prospects for Neuroprotective Therapies in Glaucoma: Drug Targets and Emerging Clinical Strategies.
Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Neurotoxic effects of dietary glutamate in glaucoma and potential nutritional and pharmacological therapies: a scoping review.International ophthalmology · 2026Article
- Cataract as an Endpoint-Dependent Confounder in Trials of Neuroprotective Therapies for Glaucoma [Letter].Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Management of glaucoma is now at an inflection point with a new generation of therapeutic candidates, whilst targeting intraocular pressure-independent strategies is challenged by the landmark Phase III failure of memantine regarding trial design and endpoint sensitivity. Preclinical research has identified promising targets including glutamate excitotoxicity, neurotrophic factor deprivation, and mitochondrial dysfunction, with nicotinamide emerging as a leading candidate due to its ability to robustly protect RGCs by supporting NAD levels and bioenergetics. Current clinical efforts are expanding into metabolic repurposing with agents (eg metformin and semaglutide), sustained-delivery systems with neurotrophic factors (eg ciliary neurotrophic factor implant), and functional enhancers (eg citicoline). To bridge the translational gap, the field is integrating new endpoints with higher sensitivity (eg advanced assessment of photopic negative response), AI-guided endpoint selection (eg graph attention neural network), novel biomarkers (eg detection of apoptotic retinal cells and neurofilament light chain in aqueous humor), and precision medicine frameworks (eg polygenic risk scores and multi-omics analysis) to develop the first clinically validated neuroprotective treatments for glaucoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.